IONS insider transaction filings
IONIS PHARMACEUTICALS INC — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-02. Screen IONS transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 24 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 1 filing by 1 insider — 20,000 shares, $1,058,700 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 13 legs across 9 filings by 9 insiders — 173,470 shares, $14,018,624 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 42.
- Largest priced transaction: sale of 50,000 shares @ $80.59 ($4,029,500) by Monia Brett P, filed 2026-06-26.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Monia Brett P — Chief Executive Officer, Director | 2 | — | 3 legs · 85,637 sh · $6,825,524 | 7 |
| Schneider Eugene — EVP, Chf Clinical Develop Ofcr | 1 | — | 1 leg · 26,000 sh · $2,107,196 | 2 |
| BENNETT C FRANK — EVP, Chief Scientific Officer | 2 | — | 2 legs · 20,536 sh · $1,744,623 | 3 |
| Hayden Michael R — Director | 2 | 2 legs · 20,000 sh · $1,058,700 | — | 2 |
| KLEIN JOSEPH III — Director | 1 | — | 2 legs · 11,518 sh · $910,416 | 4 |
| Diaz Allene M. — Director | 2 | — | 1 leg · 10,111 sh · $863,637 | 4 |
| Swayze Eric — EVP Research | 1 | — | 1 leg · 10,602 sh · $839,492 | — |
| Baroldi Joseph — EVP, Chief Business Officer | 1 | — | 1 leg · 5,635 sh · $451,699 | 4 |
| O'NEIL PATRICK R. — EVP CLO & General Counsel | 2 | — | 1 leg · 3,069 sh · $245,520 | 1 |
| Kordasiewicz Holly B. — EVP, Chief Development Officer | 1 | — | 1 leg · 362 sh · $30,517 | — |
+7 more insiders in the window, not shown — every filing appears in the table below.
Recent Form 4 filings — IONIS PHARMACEUTICALS INC
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-02 | 4 | BENNETT C FRANK — EVP, Chief Scientific Officer | Other (J): 110 @ $51.31 | EDGAR |
| 2026-09-02 | 4 | Monia Brett P — Chief Executive Officer, Director | Other (J): 98 @ $51.31 | EDGAR |
| 2026-09-02 | 4 | O'NEIL PATRICK R. — EVP CLO & General Counsel | Other (J): 63 @ $51.31 | EDGAR |
| 2026-09-02 | 4 | Birchler Brian — EVP, Corp and Development Ops | Other (J): 58 @ $51.31 | EDGAR |
| 2026-07-31 | 4 | Hayden Michael R — Director | Purchase (P): 15,000 @ $53.38 · Purchase (P): 5,000 @ $51.60 | EDGAR |
| 2026-07-17 | 4 | Reikes Peter N — Director | Grant/award (A): 3,399 (derivative) @ $0 | EDGAR |
| 2026-07-17 | 4 | HANTSON LUDWIG — Director | Grant/award (A): 3,399 (derivative) @ $0 | EDGAR |
| 2026-07-17 | 4 | HERMAN JOAN E — Director | Option exercise (M): 5,220 @ $0 · Option exercise (M): 5,220 (derivative) @ $0 | EDGAR |
| 2026-07-17 | 4 | BERTHELSEN SPENCER R — Director | Option exercise (M): 5,220 @ $0 · Option exercise (M): 5,220 (derivative) @ $0 | EDGAR |
| 2026-07-09 | 4 | Kordasiewicz Holly B. — EVP, Chief Development Officer | Sale (S): 362 @ $84.30 | EDGAR |
| 2026-07-09 | 4 | Diaz Allene M. — Director | Option exercise (M): 10,111 @ $47.11 · Sale (S): 10,111 @ $85.42 · Option exercise (M): 10,111 (derivative) @ $0 | EDGAR |
| 2026-07-09 | 4 | BENNETT C FRANK — EVP, Chief Scientific Officer | Sale (S): 5,536 @ $83.58 · Other (J): 15,000 @ $0 · Sale (S): 15,000 @ $85.46 · Other (J): 15,000 (derivative) @ $0 | EDGAR |
| 2026-07-06 | 4 | Diaz Allene M. — Director | Grant/award (A): 5,369 (derivative) @ $0 · Grant/award (A): 2,301 (derivative) @ $0 | EDGAR |
| 2026-07-06 | 4 | YANG MICHAEL J. — Director | Grant/award (A): 5,369 (derivative) @ $0 · Grant/award (A): 2,301 (derivative) @ $0 | EDGAR |
| 2026-07-06 | 4 | Hayden Michael R — Director | Grant/award (A): 5,369 (derivative) @ $0 · Grant/award (A): 2,301 (derivative) @ $0 | EDGAR |
| 2026-07-06 | 4 | LOSCALZO JOSEPH — Director | Grant/award (A): 5,369 (derivative) @ $0 · Grant/award (A): 2,301 (derivative) @ $0 | EDGAR |
| 2026-07-06 | 4 | HERMAN JOAN E — Director | Grant/award (A): 5,369 (derivative) @ $0 · Grant/award (A): 2,301 (derivative) @ $0 | EDGAR |
| 2026-07-06 | 4 | KLEIN JOSEPH III — Director | Option exercise (M): 11,518 @ $39.94 · Sale (S): 99 @ $79.45 · Sale (S): 11,419 @ $79.04 · Option exercise (M): 11,518 (derivative) @ $0 · Grant/award (A): 5,369 (derivative) @ $0 · Grant/award (A): 2,301 (derivative) @ $0 | EDGAR |
| 2026-07-06 | 4 | BERTHELSEN SPENCER R — Director | Grant/award (A): 5,369 (derivative) @ $0 · Grant/award (A): 2,301 (derivative) @ $0 | EDGAR |
| 2026-06-30 | 4 | Schneider Eugene — EVP, Chf Clinical Develop Ofcr | Option exercise (M): 26,000 @ $60.89 · Sale (S): 26,000 @ $81.05 · Option exercise (M): 26,000 (derivative) @ $0 | EDGAR |
| 2026-06-30 | 4 | Baroldi Joseph — EVP, Chief Business Officer | Option exercise (M): 3,866 @ $56.78 · Option exercise (M): 1,769 @ $32.60 · Sale (S): 5,635 @ $80.16 · Option exercise (M): 1,769 (derivative) @ $0 · Option exercise (M): 3,866 (derivative) @ $0 | EDGAR |
| 2026-06-30 | 4 | O'NEIL PATRICK R. — EVP CLO & General Counsel | Sale (S): 3,069 @ $80 | EDGAR |
| 2026-06-26 | 4 | Swayze Eric — EVP Research | Sale (S): 10,602 @ $79.18 | EDGAR |
| 2026-06-26 | 4 | Monia Brett P — Chief Executive Officer, Director | Option exercise (M): 14,565 @ $32.60 · Sale (S): 14,565 @ $78.41 · Option exercise (M): 21,072 @ $32.60 · Sale (S): 21,072 @ $78.49 · Option exercise (M): 50,000 @ $56.78 · Sale (S): 50,000 @ $80.59 · +3 more | EDGAR |
| 2026-06-16 | 4 | Kordasiewicz Holly B. — EVP, Chief Development Officer | Option exercise (M): 7,951 @ $60.89 · Option exercise (M): 21,000 @ $60.89 · Option exercise (M): 12,000 @ $32.60 · Option exercise (M): 19,895 @ $56.78 · Sale (S): 41,004 @ $73.09 · Sale (S): 19,842 @ $74.05 · +4 more | EDGAR |
| 2026-06-16 | 4 | BERTHELSEN SPENCER R — Director | Option exercise (M): 8,000 @ $24.42 · Sale (S): 8,000 @ $73.49 · Option exercise (M): 8,000 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Reikes Peter N — Director | Grant/award (A): 10,753 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | HANTSON LUDWIG — Director | Grant/award (A): 10,753 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | BERTHELSEN SPENCER R — Director | Option exercise (M): 8,000 @ $24.42 · Sale (S): 8,000 @ $75.67 · Option exercise (M): 8,000 (derivative) @ $0 | EDGAR |
| 2026-05-15 | 4 | Monia Brett P — Chief Executive Officer, Director | Option exercise (M): 1,316 @ $32.60 · Sale (S): 1,316 @ $78.01 · Option exercise (M): 3,220 @ $32.60 · Sale (S): 3,220 @ $78.68 · Option exercise (M): 1,316 (derivative) @ $0 · Option exercise (M): 3,220 (derivative) @ $0 | EDGAR |
| 2026-05-06 | 4 | LOSCALZO JOSEPH — Director | Option exercise (M): 10,968 @ $38.06 · Option exercise (M): 12,000 @ $40.05 · Option exercise (M): 10,321 @ $41.08 · Option exercise (M): 16,000 @ $42.88 · Option exercise (M): 12,000 @ $60.20 · Option exercise (M): 16,000 @ $64.80 · +8 more | EDGAR |
| 2026-05-05 | 4 | KLEIN JOSEPH III — Director | Option exercise (M): 10,111 @ $47.11 · Sale (S): 8,680 @ $73.35 · Sale (S): 1,431 @ $74.45 · Option exercise (M): 10,111 (derivative) @ $0 | EDGAR |
| 2026-04-30 | 4 | Baroldi Joseph — EVP, Chief Business Officer | Sale (S): 1,626 @ $71.79 | EDGAR |
| 2026-04-17 | 4 | Birchler Brian — EVP, Corp and Development Ops | Option exercise (M): 1,875 @ $0 · Sale (S): 973 @ $75.04 · Option exercise (M): 1,875 (derivative) @ $0 | EDGAR |
| 2026-04-17 | 4 | Baroldi Joseph — EVP, Chief Business Officer | Option exercise (M): 10,837 @ $0 · Sale (S): 5,619 @ $74.56 · Option exercise (M): 10,837 (derivative) @ $0 | EDGAR |
| 2026-04-17 | 4 | Jenne Kyle — EVP, Chf GL Pdt Str Ofcr | Option exercise (M): 12,226 @ $0 · Sale (S): 4,902 @ $75.17 · Option exercise (M): 12,226 (derivative) @ $0 | EDGAR |
| 2026-04-17 | 4 | PARSHALL B LYNNE — Director | Sale (S): 4,466 @ $76.19 · Sale (S): 534 @ $76.97 | EDGAR |
| 2026-04-02 | 4 | Devers Shannon L. — EVP, Chief Human Resources Ofc | Sale (S): 6,193 @ $74.05 | EDGAR |
| 2026-04-02 | 4 | KLEIN JOSEPH III — Director | Option exercise (M): 12,000 @ $38.06 · Option exercise (M): 10,321 @ $41.08 · Sale (S): 20,105 @ $75.50 · Sale (S): 2,216 @ $75.95 · Option exercise (M): 12,000 (derivative) @ $0 · Option exercise (M): 10,321 (derivative) @ $0 | EDGAR |
| 2026-03-23 | 4 | Schneider Eugene — EVP, Chf Clinical Develop Ofcr | Sale (S): 5,812 @ $70.97 | EDGAR |
| 2026-03-18 | 4 | HOUGEN ELIZABETH L — EVP, Finance & CFO | Option exercise (M): 60,299 @ $60.89 · Option exercise (M): 61,041 @ $56.78 · Option exercise (M): 33,118 @ $32.60 · Option exercise (M): 20,541 @ $37.58 · Sale (S): 205,608 @ $72.38 · Sale (S): 9,440 @ $72.77 · +5 more | EDGAR |
| 2026-03-11 | 4 | Jenne Kyle — EVP, Chf GL Pdt Str Ofcr | Option exercise (M): 32,602 @ $46.10 · Sale (S): 21,191 @ $75.50 · Sale (S): 16,086 @ $76.30 · Option exercise (M): 4,675 @ $34.69 · Option exercise (M): 4,675 (derivative) @ $0 · Option exercise (M): 32,602 (derivative) @ $0 | EDGAR |
| 2026-03-11 | 4 | O'NEIL PATRICK R. — EVP CLO & General Counsel | Sale (S): 10,148 @ $75.25 | EDGAR |
| 2026-03-11 | 4 | Monia Brett P — Chief Executive Officer, Director | Option exercise (M): 40,822 @ $60.89 · Option exercise (M): 73,529 @ $60.89 · Sale (S): 7,382 @ $74.11 · Sale (S): 117,604 @ $75.26 · Sale (S): 1,684 @ $75.58 · Option exercise (M): 34,103 @ $60.89 · +5 more | EDGAR |
| 2026-03-05 | 4 | Devers Shannon L. — EVP, Chief Human Resources Ofc | Option exercise (M): 3,510 @ $37.58 · Option exercise (M): 3,760 @ $40.85 · Option exercise (M): 5,500 @ $34.69 · Option exercise (M): 6,951 @ $32.60 · Option exercise (M): 385 @ $52.87 · Sale (S): 14,321 @ $79.11 · +7 more | EDGAR |
| 2026-03-05 | 4 | Baroldi Joseph — EVP, Chief Business Officer | Sale (S): 4,096 @ $79.36 · Option exercise (M): 820 @ $56.78 · Option exercise (M): 879 @ $32.60 · Sale (S): 2,088 @ $80.41 · Sale (S): 36 @ $81.01 · Option exercise (M): 238 @ $56.78 · +7 more | EDGAR |
| 2026-03-05 | 4 | Diaz Allene M. — Director | Option exercise (M): 10,321 @ $41.08 · Option exercise (M): 12,000 @ $38.06 · Option exercise (M): 18,000 @ $40.05 · Sale (S): 39,265 @ $79.11 · Sale (S): 14,608 @ $79.88 · Sale (S): 1,005 @ $80.80 · +3 more | EDGAR |
| 2026-03-05 | 4 | LOSCALZO JOSEPH — Director | Option exercise (M): 832 @ $38.06 · Sale (S): 832 @ $80.33 · Option exercise (M): 200 @ $38.06 · Sale (S): 200 @ $80 · Option exercise (M): 832 (derivative) @ $0 · Option exercise (M): 200 (derivative) @ $0 | EDGAR |
| 2026-03-05 | 4 | KLEIN JOSEPH III — Director | Option exercise (M): 12,000 @ $40.05 · Option exercise (M): 4,000 @ $42.88 · Sale (S): 13,526 @ $79.17 · Sale (S): 6,794 @ $80.00 · Sale (S): 1,012 @ $80.82 · Option exercise (M): 12,000 (derivative) @ $0 · +1 more | EDGAR |
| 2026-03-05 | 4 | BENNETT C FRANK — EVP, Chief Scientific Officer | Option exercise (M): 16,463 @ $32.60 · Option exercise (M): 48,626 @ $60.89 · Sale (S): 71,600 @ $79.10 · Sale (S): 12,687 @ $79.88 · Sale (S): 802 @ $80.76 · Option exercise (M): 16,463 (derivative) @ $0 · +1 more | EDGAR |
Recent 8-K events — IONIS PHARMACEUTICALS INC
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-04 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-04 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-29 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-10 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-09 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-24 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-12 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-08 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-28 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-29 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=IONS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →